Actions and uses of antimicrobial agents in the treatment of musculoskeletal infections.
The antimicrobial therapy of musculoskeletal infections does not differ in basic principles from the therapy of any infection. However, the chronic nature of certain of these infections and the need for long-term treatment make essential the proper selection and monitoring of the antimicrobial agents. This can be done only by obtaining proper specimens for microbiologic identification and, in many cases, by in vitro susceptibility tests of the infecting organisms. Thus, the least toxic, effective antimicrobial agent can be selected and administered without inadequate therapy or toxic side effects.
D000617:Aminoglycosides / Q000627:therapeutic use; D000666:Amphotericin B / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001847:Bone Diseases / Q000188:drug therapy*; D002511:Cephalosporins / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007239:Infections / Q000188:drug therapy; D008034:Lincomycin / Q000627:therapeutic use; D009135:Muscular Diseases / Q000188:drug therapy*; D009761:Nystatin / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D013754:Tetracyclines; D009761:Nystatin; D002981:Clindamycin; D004917:Erythromycin; D002701:Chloramphenicol; D000666:Amphotericin B; D008034:Lincomycin; D005437:Flucytosine